Chest
Clinical InvestigationsBronchodilatorsThe Combination of Ipratropium and Albuterol Optimizes Pulmonary Function Reversibility Testing in Patients With COPD
Section snippets
Materials and Methods
The PFT response rates obtained during two recently completed randomized, multicenter, double-blind, parallel group, phase III clinical trials comparing the safety and efficacy of a combination of ipratropium and albuterol to either ipratropium alone or albuterol alone were reviewed11 (data on file; Boehringer Ingelheim Pharmaceuticals Inc). Informed consent was obtained from each subject who participated in these trials.
The study groups consisted of outpatients of either sex who were 40 years
Patient Demographics
A total of 1,067 patients were enrolled in the two trials with 852 patients completing the entire study. The demographic and baseline characteristics of the 1,067 randomized patients are presented in Table 1. These patients had moderate to severe COPD with an overall FEV1 of 0.95 ± 0.41 L, which corresponds to an FEV1 percent predicted of 35.6 ± 13.6% for the group as a whole.
FEV1 Response Rate on Individual Test Days
As shown in Table 1, mean baseline values for FEV1 were comparable among the three groups and remained comparable as
Discussion
Our study confirms the hypothesis that the combination of ipratropium and albuterol results in greater PFT response rates than ipratropium or albuterol alone in patients with COPD. Specifically, the data demonstrate that whether a significant PFT response is defined as a 12% or a 15% increase in FEV1 compared with baseline values, the combination of ipratropium plus albuterol is superior to the individual agents. In addition, the superior PFT response rate observed with the combination of
References (19)
Current thoughts regarding treatment of chronic obstructive pulmonary disease
Med Clin North Am
(1996)- et al.
Fifteen-year interval spirometric evaluation of the Oregon predictive equations
Chest
(1988) - et al.
Extended therapy with ipratropium is associated with improved lung function in patients with COPD
Chest
(1996) - et al.
Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease
Am J Respir Crit Care Med
(1995) - et al.
Management of chronic obstructive pulmonary disease
N Engl J Med
(1993) - et al.
Interpretation of bronchodilator response in patients with obstructive airways disease
Thorax
(1992) - et al.
A comparison of six different ways of expressing the bronchodilating response in asthma and COPD: reproducibility and dependence of prebronchodilator FEV1
Eur Respir J
(1992) - et al.
Diagnostic value of reversibility of chronic airway obstruction to separate asthma from chronic bronchitis: a statistical approach
Eur Respir J
(1989) - et al.
Clinical interpretation of airway response to a bronchodilator
Am Rev Respir Dis
(1986)
Cited by (82)
Quantitative and qualitative evaluation of spirometry for COPD screening in general practice
2020, Respiratory Medicine and ResearchAcute bronchodilator responses to β2-agonist and anticholinergic agent in COPD: Their different associations with exacerbation
2017, Respiratory MedicineCitation Excerpt :Therefore, the criterion that incorporates both absolute and percentage increase in FEV1, as used in this study, would be the most appropriate for the nature of airway reversibility in COPD subjects. In comparison with previous reports [2,4,9,12], the rate of subjects in our population who fulfilled the reversibility criteria at each visit was low, and this subsequently caused a low percentage of subjects with consistent reversibility over three visits. Of note, this study carefully excluded subjects with respiratory specialist-diagnosed asthma who may potentially have high BDR values, based on the absence of asthma history and/or respiratory symptoms, and this could be a possible explanation for the discrepancy.
COPD: Clinical Diagnosis and Management
2015, Murray and Nadel's Textbook of Respiratory Medicine: Volume 1,2, Sixth EditionEffects of long-acting bronchodilators and prednisolone on inspiratory lung function parameters in stable COPD
2014, Pulmonary Pharmacology and TherapeuticsPreclinical efficacy of THRX-200495, a dual pharmacology muscarinic receptor antagonist and β<inf>2</inf>-adrenoceptor agonist (MABA)
2012, Pulmonary Pharmacology and Therapeutics
Drs. Dorinsky, Reisner, Menjoge, Serby, and Witek were, at the time of this study, employed by Boehringer Ingelheim Pharmaceuticals, Inc, maker of the Combivent brand of ipratropium bromide and albuterol.
- †
Currently at Glaxo Wellcome, Research Triangle Park, NC.